Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lannett Enters Supply And Distribution Agreement For Levothyroxine

Executive Summary

Lannett enters into an agreement with Cediprof for an exclusive 10-year future supply and distribution agreement of levothyroxine starting 1 August 2022.

You may also be interested in...

Lannett Launches Authorized Tirosint In US

Lannett has launched levothyroxine sodium capsules, an authorized generic version of Tirosint, in partnership with IBSA in the US. The company faces the possibility of competition, as Teva may enter the market with certain generic strengths.

Lannett Will Close Cody Site After Failing To Find Buyer

Having failed to find a buyer for its raw materials business in Cody, US, Lannett now intends to shut down the operation.

Lannett Sees Profit Dive But Retains ‘Positive’ Outlook

US firm Lannett, which recently lost a key distribution deal involving a highly profitable thyroid drug, raised its sales guidance for fiscal 2019 and was upbeat on its prospects after reporting third-quarter net profit that fell by 17% to $10.6m.

Related Content


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts